

Clopidogrel (Plavix[®])

No. 88/04

Sanofi-Synthelabo and Bristol-Myers Squibb

Indication: prevention of atherothrombotic events in acute coronary syndrome (without ST-segment elevation) in combination with aspirin.

Summary of Recommendation

8 February, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Clopidogrel (Plavix) is accepted for restricted use within NHS Scotland for the treatment of acute coronary syndrome (without ST-segment elevation) in combination with aspirin. It should be initiated only during an inpatient stay and only in patients in whom a diagnosis of acute coronary syndrome is confirmed with ECG changes or raised cardiac enzymes/markers. The maximum benefit appears within 3 months of starting treatment and the available information suggests that there is loss of benefit on stopping treatment. Benefits are greatest in patients with a high Thrombosis In Myocardial Infarction (TIMI) risk score (5 – 7).

Professor David H Lawson
Chairman